Monday, May 23, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

DoD Awards Funding to Pulmotect to Study Repurposed PUL-042 Against COVID-19

by Global Biodefense Staff
January 27, 2021
Test tubes and dropper

Credit: Shutterstock

The Department of Defense (DOD) awarded a $6 million agreement to Pulmotect, Inc., a clinical-stage biotechnology company, to execute two ongoing Phase II trials addressing COVID-19.

PUL-042, a synergistic combination of two toll-like receptor agonists, activates the
lungs’ surface immune system. As microbes, including viruses, land on the epithelial cells of the lung lining, they are destroyed on-contact by antimicrobial peptides and reactive oxygen species (ROS), including superoxides, that are released by epithelial cells. PUL042 has demonstrated protection against a broad range of respiratory pathogens in preclinical models, including the coronaviruses that cause MERS and SARS.

“We are delighted to receive funding from the Department of Defense to complete these clinical trials, both of which are enrolling participants at clinical sites in
the U.S.,” said Dr. Colin Broom, CEO of Pulmotect. “We appreciate the support to evaluate PUL-042, which not only has the potential to be effective against SARS-CoV-2 but also also has potential for use against other pathogens that infect the respiratory tract.”

If the clinical trials generate positive data, Pulmotect will submit an emergency use authorization (EUA) to the U.S. Food and Drug Administration (FDA) for PUL-042 as a COVID-19 therapeutic in 2021.

The first study will test the prophylactic capabilities of PUL-042 by evaluating the efficacy and safety of the drug in reducing the infection rate of SARS-CoV-2 and its progression to COVID-19. The second is a therapeutic study testing the effectiveness of PUL-042 to reduce the severity of the disease in those with early and/or mild COVID-19 infection. 

The agreement was executed by the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM CBRN Medical) through the Medical CBRN Defense Consortium, in collaboration with U.S. Army Contracting Command-New Jersey (W15QKN-16-9-1002, Project #MCDC 2006-002).

“The repurposing of this agent advances the fight against COVD-19, with the potential to protect our service members during this unprecedented pandemic,” said Col. Ryan Eckmeier, the Joint Project Manager for CBRN Medical. “Facilitating our government and industry partners to help find a way to tackle this threat is a necessary action to reduce the spread of this disease.”

Pulmotect is developing PUL-042, a clinical stage, first-in-class, inhaled, immunomodulatory agent. A synergistic agonist that amplifies the innate immune defenses of the lung epithelial mucosa to provide broad-spectrum, pathogen-agnostic protection against respiratory infections. Invented at UT MD Anderson Cancer Center/Texas A&M University, PUL-042 has patents issued in 10 countries, both as a stand-alone composition of matter product and in combination with antivirals. PUL-042 R&D has been supported by the National Institutes of Health (NIAID, NIGMS), the Cancer Prevention and Research Institute of Texas (CPRIT), and other funding agencies.

Tags: Clinical TrialsCOVID CountermeasuresCOVID-19Editor PickJPEO-CBRNDSARS-CoV-2

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity
Biosecurity

U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity

April 13, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC